CANNABIS E MALATTIE NEURODEGENERATIVE
Riportiamo di seguito uno studio realizzato da Neurologi di Università USA del Texas e del Colorado, circa il trattamento di disordini del movimento in patologie neurologiche gravi quali: Morbo di Parkinson, Malattia di Huntington, Sin drome di Tourette.
Anche qui i risultati sono contradditori e incoraggiano la ricerca affinché fornisca maggiori dettagli e certezze, circa l’uso terapeutico della Cannabis
Movement Disorders, Vol. 30, No. 3, 2015
The Therapeutic Potential of Cannabinoids for Movement Disorders
Benzi Kluger, MD, MS,1†* Piera Triolo, BS,1† Wallace Jones, BS,1† and Joseph Jankovic, MD2†
1Movement Disorders Center, Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA
2Parkinson’s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA
Several factors may help explain conflicting preclinical results. Given that cannabinoids interact with a wide range of pharmacological targets, discrepancies in data obtained from preclinical studies may partly reflect the multiplicity of cannabinoid actions. The complex localization of cannabinoid receptors at different sites in basal ganglia circuits and the broad array of formulations and doses used in preclinical and clinical studies may also help explain contradictory results. Future clinical trials should be adequately powered, employ appropriate methodology and outcome measures for the specific movement disorder studied, and assess blinding adequacy. Improved knowledge of cannabinoids and their pharmacology may help identify specific cannabinoids or combinations that provide therapeutic or neuroprotective benefits in patients with movement disorders.
[image credit: neurochatt.com]